Statin use in chronic heart failure: Waiting for the results of large prospective outcome trials

International Journal of Cardiology

Volumn 132, Issue 1, 2009, Pages 122-124

  Celik, Turgay ^a   Iyisoy, Atila ^a   Dogru, M Tolga ^b   ISIK, Ersoy ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; PLACEBO; ROSUVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART FUNCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; EVIDENCE-BASED MEDICINE; FATTY ACIDS, MONOUNSATURATED; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INDOLES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 58849123860     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.06.122     Document Type: Article

References (17)

1. Gurgun C., Ildizli M., Yavuzgil O., et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol (Feb 21 2007) [Epub ahead of print]
2. Raina A., Pickering T., and Shimbo D. Statin use in heart failure: a cause for concern?. Am Heart J 152 (2006) 39-49
3. Gheorghiade M., and Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97 (1998) 282-289
4. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
5. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
6. Oi S., Haneda T., Osaki J., et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 376 (1999) 139-148
7. Luo J.D., Zhang W.W., Zhang G.P., Guan J.X., and Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 26 (1999) 903-908
8. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1978
9. Nickenig G., Baumer A.T., Temur Y., Kebben D., Jockenhovel F., and Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100 (1999) 2131-2134
10. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
11. Laufs U., Wassmann S., Schackmann S., Heeschen C., Bohm M., and Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 93 (2004) 103-108
12. Tousoulis D., Antoniades C., Bosinakou E., et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 178 (2005) 359-363
13. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama 285 (2001) 1711-1718
14. Lipinski M.J., Abbate A., Fuster V., and Vetrovec G.W. Drug insight: statins for nonischemic heart failure-evidence and potential mechanisms. Nat Clin Pract Cardiovasc Med 4 (2007) 196-205
15. Tavazzi L., Tognoni G., Franzosi M.G., et al. GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6 (2004) 635-641
16. Kjekshus J., Dunselman P., Blideskog M., et al. CORONA Study Group. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7 (2005) 1059-1069
17. Cleland J.G., Coletta A.P., Nikitin N.P., and Clark A.L. Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur J Heart Fail 8 (2006) 326-329